- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic
- Interventions
- Eltrekibart, Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 55
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- Placebo, Remdesivir, Risankizumab
- Other · Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more
- Conditions
- Psoriasis Vulgaris
- Interventions
- Tildrakizumab
- Biological
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Psoriasis
- Interventions
- Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit
- Drug · Procedure
- Lead sponsor
- Jaehwan Kim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Sacramento, California • New York, New York
- Conditions
- Psoriasis
- Interventions
- Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Drug
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
- Conditions
- Psoriasis
- Interventions
- Group #2 (Intervention), Group #3 (Intervention)
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Psoriasis
- Interventions
- Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more
- Conditions
- Psoriasis
- Interventions
- ustekinumab, placebo
- Drug
- Lead sponsor
- Centocor Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
- Conditions
- Psoriasis Vulgaris
- Interventions
- Tildrakizumab Prefilled Syringe
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Orange, California • San Francisco, California • Denver, Colorado + 18 more
- Conditions
- Psoriasis, Cardiovascular Disease
- Interventions
- Tildrakizumab
- Drug
- Lead sponsor
- Marcelo F. Di Carli, MD, FACC
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD)
- Interventions
- Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23
- Drug
- Lead sponsor
- Specialty Networks Research.
- Network
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Sun City, Arizona • Glenview, Illinois • Gurnee, Illinois + 8 more
- Conditions
- Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab SC, Mirikizumab IV, Placebo SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 57
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Hartford, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Crohn's Disease
- Interventions
- Placebo (IP), Ustekinumab 1mg/kg (IP), Ustekinumab 3 mg/kg (IP), Ustekinumab 6 mg/kg (IP), Placebo IV - Responder - Placebo SC (MP), Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP), Ustekinumab IV - Responder - Placebo SC (MP), Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP), Ustekinumab IV - Nonresponder - Placebo SC (MP), Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 88
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • La Jolla, California + 85 more
- Conditions
- Psoriasis
- Interventions
- Mirikizumab, Placebo, Secukinumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more
- Conditions
- Plaque Psoriasis
- Interventions
- Bimekizumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- East Windsor, New Jersey • New York, New York
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Abatacept, UST Placebo, ABA Placebo
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more
- Conditions
- Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
- Interventions
- mRNA-2752, Durvalumab
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 16
- States / cities
- San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
- Conditions
- Psoriasis
- Interventions
- LY2525623 Intravenous, LY2525623 Subcutaneous, Placebo Intravenous, Placebo Subcutaneous
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Mobile, Alabama • Peoria, Arizona • Hot Springs, Arkansas + 17 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 98
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Interventions
- Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 74 more
- Conditions
- Crohn's Disease, Perianal Fistula
- Interventions
- Mirikizumab, Fistula Tract Curettage and Closure
- Drug · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Louis, Missouri • New York, New York